8238 related articles for article (PubMed ID: 19679015)
21. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
22. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
23. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Wolchok JD; Hoos A; O'Day S; Weber JS; Hamid O; Lebbé C; Maio M; Binder M; Bohnsack O; Nichol G; Humphrey R; Hodi FS
Clin Cancer Res; 2009 Dec; 15(23):7412-20. PubMed ID: 19934295
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy and the concept of a clinical cure.
Eggermont AM; Kroemer G; Zitvogel L
Eur J Cancer; 2013 Sep; 49(14):2965-7. PubMed ID: 23890942
[TBL] [Abstract][Full Text] [Related]
25. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
Barker CA; Postow MA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
28. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy--revisited.
Lesterhuis WJ; Haanen JB; Punt CJ
Nat Rev Drug Discov; 2011 Aug; 10(8):591-600. PubMed ID: 21804596
[TBL] [Abstract][Full Text] [Related]
30. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
31. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
Blank CU
Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
[TBL] [Abstract][Full Text] [Related]
32. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of melanoma: an update.
Homsi J; Grimm JC; Hwu P
Surg Oncol Clin N Am; 2011 Jan; 20(1):145-63. PubMed ID: 21111964
[TBL] [Abstract][Full Text] [Related]
35. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Fong L; Small EJ
J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
[TBL] [Abstract][Full Text] [Related]
36. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
37. Modulation of CTLA-4 and GITR for cancer immunotherapy.
Avogadri F; Yuan J; Yang A; Schaer D; Wolchok JD
Curr Top Microbiol Immunol; 2011; 344():211-44. PubMed ID: 20563707
[TBL] [Abstract][Full Text] [Related]
38. Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases.
Wilgenhof S; Pierret L; Corthals J; Van Nuffel AM; Heirman C; Roelandt T; De Coninck A; Verfaillie G; Vandenbroucke F; Van Riet I; Bonehill A; Thielemans K; Neyns B
Melanoma Res; 2011 Apr; 21(2):152-9. PubMed ID: 21317818
[TBL] [Abstract][Full Text] [Related]
39. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
